Prevelance, Predictors and Outcome of Sepsis Associated Liver Injury (SALI)

December 28, 2024 updated by: Mahmoud sayed Zohry Sayed, Assiut University
prevelance, predictors and outcome of sepsis associated liver injury (SALI)

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

patient with liver disease and sepsis at the same time

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mahmoud sayed zohry, first mastar
  • Phone Number: 01069209843 01225463889
  • Email: mzohry789@yahoo.com

Study Contact Backup

  • Name: Dinal ali hamad dina hamad, specialist
  • Phone Number: 01063040703
  • Email: dinaalihamad@aun.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

all people between 15 to 75 years

Description

Inclusion Criteria:

  • clinical diagnosis of SALI
  • must take liver support

Exclusion Criteria:

  • SALI
  • Thyroid disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
SALI
Device: Antibiotic
SALI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
prevelance, predictors and outcome of sepsis associated liver injury (SALI)
Time Frame: baseline
analysis outcome of sepsis associated liver injury (SALI)
baseline
28 days mortality
Time Frame: baseline
patient with liver dieases and sepsis
baseline
patient shouldn't be in pain
Time Frame: baseline
patient in study not in pain
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
patient stay in hospital 2weeks
Time Frame: baseline
patient with liver dieases and sepsis
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Collaborators

Investigator

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

December 14, 2024

First Submitted That Met QC Criteria

December 28, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 28, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • prevelance ,predictors of SALI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Injuries

Clinical Trials on Antibiotic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe